Matt Evola
Subscribe to Matt Evola's PostsMatt Evola assists clients with premerger analysis and notification under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act and in defending mergers and acquisitions before the US Federal Trade Commission (FTC), US Department of Justice (DOJ), state antitrust authorities and foreign competition authorities. He also counsels clients in relation to complex antitrust litigation and government investigations. Matt has experience in a variety of industries, including representing clients in the healthcare, pharmaceutical, packaging, aggregates, consumer products, and telecommunications industries. Read Matt Evola's full bio.
Antitrust M&A Snapshot | Q4 2023
By Claire Danberg, Emilia Bonine, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Matt Evola and Max Küttner on Feb 14, 2024
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: New Merger Guidelines Released FTC Focused on Pharmaceutical Companies FTC Targets “Moat-Building” Mergers Fifth Circuit Fuels FTC’s Vertical Mergers Agenda FTC Losing Streak Reverses During the Fourth Quarter Ex post Review in the Merger Control Sphere Occurring More and More Frequently Access the full issue.
Continue Reading
The Fix Is In – Key Learnings From Recent Vertical Merger Challenges
By Jon B. Dubrow, Stephen Wu, Matt Evola and Bailey K. Sanders on Feb 9, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Vertical mergers are inherently more difficult for the government to litigate than horizonal mergers. After not litigating a vertical merger case since the 1970s, the Federal Trade Commission and the US Department of Justice have recently tried several matters. In this Westlaw Today article, Jon Dubrow, Stephen Wu, Matt Evola and Bailey Sanders discuss key...
Continue Reading
Antitrust M&A Snapshot | Q2 2023
By Graham Hyman, Mary Hecht, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet, Matt Evola and Max Küttner on Jul 31, 2023
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: FTC Unveils Proposal Detailing Significant Changes to Hart-Scott-Rodino Act Merger Notifications Assa Abloy Settlement Raises Questions on Litigating the Fix and DOJ Consent Decrees Pharmaceutical Industry Remains in Regulators’ Crosshairs “Whole of Government” Competition Mandate Can Impact Deals the FTC and DOJ Do Not Challenge FTC’s Constitutionality Comes Under Fire—Again...
Continue Reading
Antitrust M&A Snapshot | Q1 2023
By Anthony S. Ferrara, Max Küttner, Jon B. Dubrow, Joel R. Grosberg, Stéphane Dionnet and Matt Evola on Apr 20, 2023
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
Topics covered in this edition: Christine Wilson Resigns as FTC Commissioner FTC/Department of Justice Horizontal Merger Guidelines Delayed Agencies Maintain Focus on Private Equity, Especially in Healthcare Continuing a Trend: FTC Loses Challenge to Meta’s Acquisition of Within Agencies Continue to Challenge Transactions Outright Rather than Negotiate Settlements New Regulatory Burden: The EU Foreign Subsidies...
Continue Reading
Antitrust M&A Snapshot | Q4 2022
By Alexandra Lewis, Jon B. Dubrow, Joel R. Grosberg and Matt Evola on Jan 19, 2023
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Mergers & Acquisitions
Topics covered in this edition: • DOJ Sees First Merger Win After String of Losses • FTC Brings Suit Against Microsoft/Activision • Updated Merger Guidelines Expected Soon • Merger Fees Changing • The EC Launches a Consultation on Its Draft Revised Market Definition Notice • UK Orders a Chinese Firm to Divest Its 83% Controlling...
Continue Reading
Antitrust M&A Snapshot | Q3 2022
By Reese Poncia, Carina Kant, Jon B. Dubrow, Joel R. Grosberg and Matt Evola on Nov 18, 2022
Posted In DOJ Developments, EC Developments, EU Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
In the United States, the US Department of Justice (DOJ) and the Federal Trade Commission (FTC) lost four merger challenges (Illumina/GRAIL, UnitedHealth/Change Healthcare, U.S. Sugar/Imperial Sugar and Booz Allen/EverWatch) in September. The losses demonstrate that parties willing to litigate can have success in court. The absence of “smoking gun” documents and lack of a presumption...
Continue Reading
Why Courts Are Rejecting Agencies’ Merger Challenges
By Jon B. Dubrow, Joel R. Grosberg and Matt Evola on Oct 24, 2022
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
The US Department of Justice’s and the Federal Trade Commission’s losses in three merger challenges in September and a fourth in October demonstrate that merging parties can close difficult transactions if willing to fight the agencies in court. In this Law360 article, McDermott’s Jon B. Dubrow, Joel R. Grosberg and Matt Evola discuss these four cases...
Continue Reading
Antitrust M&A Snapshot | Q4 2021
By Matt Evola, Mary Hecht, Jon B. Dubrow, Joel R. Grosberg and Lisa P. Rumin on Feb 1, 2022
Posted In DOJ Developments, EC Developments, EU Developments, French Developments, FTC Developments, Mergers & Acquisitions
In the United States, antitrust agencies have now filled senior leadership positions, although the Federal Trade Commission (FTC) awaits the appointment of a fifth commissioner. Challenges to mergers continue apace at both the FTC and the Department of Justice (DOJ). The agencies challenged two mergers in the fourth quarter and a third transaction was abandoned....
Continue Reading
THE LATEST: Antitrust Agencies Show Frustration with Slow Divestitures
By Gregory E. Heltzer and Matt Evola on Jul 14, 2020
Posted In DOJ Developments, FTC Developments, Mergers & Acquisitions
The US Federal Trade Commission (FTC) recently extracted a $3.5 million civil penalty from two companies involved in a gas station merger. The FTC asserts the companies violated their settlement agreement with the government, which required the divestment of 10 gas stations within 120 days from the date of the settlement agreement. The parties overshot...
Continue Reading
Close Scrutiny for Class Settlements Where Plaintiff Attorneys Take Lion’s Share
By Nicole Castle, Michelle Lowery, Matt Evola, Stephen Wu and McDermott Will & Emery on Jan 27, 2020
Posted In Cartel Enforcement, Private Litigation
Two recent US antitrust class action settlements drew additional scrutiny from federal judges, showing that the allocation of settlement funds between a proposed class and their attorneys will be carefully reviewed for fairness to class members.
Continue Reading
